Heregulin regulates prolactinoma gene expression

Cancer Research

Volumn 69, Issue 10, 2009, Pages 4209-4216

  Vlotides, George ^a   Cooper, Odelia ^a   Chen, Yen Hao ^a   Ren, Song Guang ^a   Greenman, Yona ^b   Melmed, Shlomo ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GEFITINIB; GROWTH HORMONE; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; PROLACTIN; PROTEIN P185; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; IMMUNOFLUORESCENCE TEST; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROLACTIN SECRETING CELL; PROLACTINOMA; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RAT; UPREGULATION;

ACTINS; ANIMALS; BETA 2-MICROGLOBULIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONIDASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; GROWTH HORMONE; HUMANS; NEUREGULIN-1; PITUITARY GLAND; PITUITARY NEOPLASMS; POLYMERASE CHAIN REACTION; PROLACTIN; PROLACTINOMA; RATS; RATS, INBRED WF; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 66249127952     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4934     Document Type: Article

References (47)

1. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485-534. (Pubitemid 44213229)
2. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 2003;112:1603-1618 (Pubitemid 38063716)
3. Olafsdottir A, Schlechte J. Management of resistant prolactinomas. Nat Clin Pract Endocrinol Metab 2006;2:552-561 (Pubitemid 44536603)
4. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005;90:3089-3099 (Pubitemid 40686369)
5. Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF, Jr., Lloyd RV. Pituitary carcinoma: a clinicopathological review. Neurosurgery 2005;56:1066-74; discussion -74. (Pubitemid 40628116)
6. Kars M, Roelfsema F, Romijn JA, Pereira AM. Malignant prolactinoma: case report and review of the literature. Eur J Endocrinol 2006;155:523-534 (Pubitemid 44636871)
7. Zhang H, Berezov A, Wang Q, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007;117:2051-2058 (Pubitemid 47224766)
8. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-5287 (Pubitemid 26315047)
9. LeRiche VK, Asa SL, Ezzat S. Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J Clin Endocrinol Metab 1996;81:656-662 (Pubitemid 26055681)
10. Jaffrain-Rea ML, Petrangeli E, Lubrano C, et al. Epidermal growth factor binding sites in human pituitary macroadenomas. J Endocrinol 1998;158:425-433 (Pubitemid 28407550)
11. Nose-Alberti V, Mesquita MI, Martin LC, Kayath MJ. Adrenocorticotropin- producing pituitary carcinoma with expression of c-erbB-2 and high PCNA index: a comparative study with pituitary adenomas and normal pituitary tissues. Endocr Pathol 1998;9:53-62. (Pubitemid 28304406)
12. Roncaroli F, Nose V, Scheithauer BW, et al. Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. Report of two cases. J Neurosurg 2003;99:402-408 (Pubitemid 36900136)
13. Onguru O, Scheithauer BW, Kovacs K, et al. Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. Mod Pathol 2004;17:772-780 (Pubitemid 38843359)
14. Vlotides G, Siegel E, Donangelo I, Gutman S, Ren S, Melmed S. Rat Prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res 2008;68:6377-6386
15. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043 (Pubitemid 46799492)
16. Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-441 (Pubitemid 46160912)
17. Drebin JA, Stern DF, Link VC, Weinberg RA, Greene MI. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 1984;312:545-548 (Pubitemid 15182282)
18. Dobashi K, Weiner DB, Greene MI. Differential regulation of oncogenic and cellular p185 by serine/threonine kinases. DNA 1989;8:723-732 (Pubitemid 20025293)
19. Anido J, Matar P, Albanell J, et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 2003;9:1274-1283 (Pubitemid 36418377)
20. Hirata A, Hosoi F, Miyagawa M, et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 2005;65:4253-4260 (Pubitemid 40775664)
21. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265-273 (Pubitemid 44079693)
22. Birman P, Michard M, Li JY, Peillon F, Bression D. Epidermal growth factor-binding sites, present in normal human and rat pituitaries, are absent in human pituitary adenomas. J Clin Endocrinol Metab 1987;65:275-281 (Pubitemid 17103010)
23. Peillon F, Le Dafniet M, Garnier P, et al. Receptors and neurohormones in human pituitary adenomas. Horm Res 1989;31:13-18 (Pubitemid 19125698)
24. Halper J, Parnell PG, Carter BJ, Ren P, Scheithauer BW. Presence of growth factors in human pituitary. Lab Invest 1992;66:639-645
25. Chaidarun SS, Eggo MC, Sheppard MC, Stewart PM. Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. Endocrinology 1994;135:2012-2021 (Pubitemid 24363897)
26. Kontogeorgos G, Stefaneanu L, Kovacs K, Cheng Z. Localization of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFr) in human pituitary adenomas and nontumorous pituitaries: an immunocytochemical study. Endocr Pathol 1996;7:63-70. (Pubitemid 126717328)
27. Theodoropoulou M, Arzberger T, Gruebler Y, et al. Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol 2004;183:385-394 (Pubitemid 39562718)
28. Ezzat S, Zheng L, Smyth HS, Asa SL. The c-erbB-2/neu proto-oncogene in human pituitary tumours. Clin Endocrinol (Oxf) 1997;46:599-606. (Pubitemid 27286933)
29. Botelho CH, Magalhaes AV, Mello PA, Schmitt FC, Casulari LA. Expression of p53, Ki-67 and c-erb B2 in growth hormone- and/or prolactin-secreting pituitary adenomas. Arq Neuropsiquiatr 2006;64:60-66
30. Borgundvaag B, Kudlow JE, Mueller SG, George SR. Dopamine receptor activation inhibits estrogen-stimulated transforming growth factor-α gene expression and growth in anterior pituitary, but not in uterus. Endocrinology 1992;130:3453-3458
31. McAndrew J, Paterson AJ, Asa SL, McCarthy KJ, Kudlow JE. Targeting of transforming growth factor-α expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas. Endocrinology 1995;136:4479-4488
32. Li Z, Mei Y, Liu X, Zhou M. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners. Cell Signal 2007;19:466-471 (Pubitemid 46111022)
33. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-516 (Pubitemid 44036456)
34. Lemke GE, Brockes JP. Identification and purification of glial growth factor. J Neurosci 1984;4:75-83.
35. Kopchick JJ. Growth hormone. In: DeGroot LJ, Jameson JL, editors. Endocrinology, 5th ed. Vol.1. Philadelphia: Elsevier Saunders; 2006. p. 579-599
36. Cronin MJ, Faure N, Martial JA, Weiner RI. Absence of high affinity dopamine receptor in GH3 cells: a prolactin-secreting clone resistant to the inhibitory action of dopamine. Endocrinology 1980;106:718-723 (Pubitemid 10135099)
37. Musat M, Korbonits M, Kola B, et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer 2005;12:423-433 (Pubitemid 40896456)
38. Hubina E, Nanzer AM, Hanson MR, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol 2006;155:371-379 (Pubitemid 44269455)
39. Conrad KE, Oberwetter JM, Vaillancourt R, Johnson GL, Gutierrez-Hartmann A. Identification of the functional components of the Ras signaling pathway regulating pituitary cell-specific gene expression. Mol Cell Biol 1994;14:1553-1565 (Pubitemid 24074551)
40. Wang YH, Jue SF, Maurer RA. Thyrotropin-releasing hormone stimulates phosphorylation of the epidermal growth factor receptor in GH3 pituitary cells. Mol Endocrinol 2000;14:1328-1337
41. Pickett CA, Gutierrez-Hartmann A. Epidermal growth factor and Ras regulate gene expression in GH4 pituitary cells by separate, antagonistic signal transduction pathways. Mol Cell Biol 1995;15:6777-6784
42. Ben-Jonathan N, Chen S, Dunckley JA, Lapensee C, Kansra S. Estrogen receptor {a} mediates the epidermal growth factor-stimulated prolactin expression and release in lactotrophs. Endocrinology 2009;150:795-802.
43. Duval DL, Gutierrez-Hartmann A. PRL-releasing peptide stimulation of PRL gene transcription-enter AKT. Endocrinology 2002;143:11-12 (Pubitemid 34056397)
44. Schreiber S, Saeger W, Ludecke DK. Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary 1999;1:213-220
45. Kovacs K, Horvath E, Syro LV, et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 2007;38:185-189
46. Neff LM, Weil M, Cole A, et al. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 2007;10:81-86 (Pubitemid 46562811)
47. Goffin V, Touraine P, Culler MD, Kelly PA. Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nat Clin Pract Endocrinol Metab 2006;2:571-581